Close

Aptose Biosciences (APTO) Reports Exclusive License Agreement for Dual BET/Kinase Targeting Program With OHM Oncology

March 7, 2018 7:12 AM EST Send to a Friend
Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login